https://www.benzinga.com/views/taxonomy/term/30777 en https://www.benzinga.com/pressreleases/26/05/g52797244/medicinova-announces-completion-of-last-patient-last-visit-in-the-mn-001-natg-202-clinical-trial-o?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="justify">LA JOLLA, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/MNOV" rel="nofollow">MNOV</a>) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the completion of last patient last visit (LPLV) in its Phase 2 clinical trial, MN-001-NATG-202, evaluating MN-001 (tipelukast) for the treatment of hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus (T2DM).</p> <p>The MN-001-NATG-202 study is a multicenter, randomized, double-blind, placebo-controlled trial evaluating MN-001 (tipelukast). Patients were randomized 1:1 to receive either 500 mg/day of MN-001 (tipelukast) or placebo for 24 weeks.　The co-primary endpoints are (1) change from baseline in liver fat content, as measured by controlled attenuation parameter (CAP) score, at Week 24, and (2) change from baseline in fasting serum triglycerides at Week 24. Secondary endpoints include safety, tolerability, and changes in lipid profile (HDL-C, LDL-C, and total cholesterol). Top-line data are expected in the third quarter of 2026.</p> <p><strong>About</strong> <strong>MN-</strong><strong>001</strong></p> <p align="justify">MN-001 (tipelukast) is a novel, orally bioavailable, small-molecule compound thought to exert its effects through several mechanisms to produce anti-inflammatory and antifibrotic activity in preclinical models, including leukotriene (LT) receptor antagonism, inhibition of phosphodiesterase (PDE) (mainly 3 and 4), and inhibition of 5-lipoxygenase (5-LO). The 5-LO/LT pathway has been postulated as a pathogenic factor in fibrosis development, and MN-001&#39;s inhibitory effect on 5-LO and the 5-LO/LT pathway is a novel approach to treating fibrosis. MN-001 has been shown to down-regulate expression of genes that promote fibrosis, including LOXL2, Collagen Type 1, and TIMP-1. MN-001 has also been shown to down-regulate expression of genes that promote inflammation, including CCR2 and MCP-1. It also inhibits triglyceride synthesis in hepatocytes by inhibiting arachidonic acid uptake. Recent research suggested that MN-002, the major metabolite of MN-001, significantly enhanced cholesterol efflux in macrophages by upregulating key transport ...</p><p><a href=https://www.benzinga.com/pressreleases/26/05/g52797244/medicinova-announces-completion-of-last-patient-last-visit-in-the-mn-001-natg-202-clinical-trial-o?utm_source=benzinga_taxonomy&amp;utm_medium=rss_feed_free&amp;utm_content=taxonomy_rss&amp;utm_campaign=channel alt=MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)>Full story available on Benzinga.com</a></p> MNOV Retail Sales Analyst Ratings Press Releases Tue, 26 May 2026 23:00:00 +0000 Globe Newswire 52797244 at https://www.benzinga.com https://www.benzinga.com/pressreleases/26/05/n52795502/sola-salons-builds-q1-momentum-with-new-signings-openings-and-enhanced-2026-fdd?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel <p xmlns="http://www.w3.org/1999/xhtml" class="prntac"><i xmlns="http://www.w3.org/1999/xhtml">New Signings and Openings Drive Early-Year Growth as Enhanced FDD Offers Clearer Visibility into the Sola Salons Investment Opportunity</i></p> <p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">DENVER</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">May 26, 2026</span> /PRNewswire/ -- <a xmlns="http://www.w3.org/1999/xhtml" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4696935-1&amp;h=2306835684&amp;u=https%3A%2F%2Fwww.solasalonstudios.com%2F&amp;a=Sola+Salons" target="_blank" rel="nofollow" rel="nofollow">Sola Salons</a>, the world&#39;s largest salon studio suite concept and home to more than 21,000 independent beauty and wellness professionals, is continuing its strong growth trajectory in 2026, marked by new franchise signings, multiple studio openings, and the release of its enhanced Franchise Disclosure Document (FDD), providing prospective franchisees with a clearer view into the brand&#39;s investment profile and long-term performance.</p> <div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p xmlns="http://www.w3.org/1999/xhtml"> <a xmlns="http://www.w3.org/1999/xhtml" href="https://mma.prnewswire.com/media/2988180/Sola_Salons_Logo.html" target="_blank" rel="nofollow" rel="nofollow"><br /> <img xmlns="http://www.w3.org/1999/xhtml" src="https://mma.prnewswire.com/media/2988180/Sola_Salons_Logo.jpg" title="Sola Salons" alt="Sola Salons" /><br /> </a> </p> </div> <p xmlns="http://www.w3.org/1999/xhtml">&#34;We are seeing strong demand from both new and existing franchisees who understand the strength of the Sola model and continue to reinvest in it,&#34; said Keith Sizemore, Chief Development Officer of Sola Salons. &#34;With the updates to our FDD, we are giving prospective owners a clearer view into the economics so they can move forward with confidence.&#34;</p> <p xmlns="http://www.w3.org/1999/xhtml">The brand&#39;s Q1 development activity reflects continued demand from both new and existing operators. New agreements include:</p> <ul xmlns="http://www.w3.org/1999/xhtml" type="disc"> <li xmlns="http://www.w3.org/1999/xhtml">Three-unit expansion in Salt Lake City from <b xmlns="http://www.w3.org/1999/xhtml">Mary and Clark Rasmussen</b>, who bring a unique combination of medical and aesthetics experience to their ownership journey</li> <li xmlns="http://www.w3.org/1999/xhtml">New franchisees <b xmlns="http://www.w3.org/1999/xhtml">Meghan and Jeff Wallace</b>, who are transitioning from Sola beauty pro-ownership into franchising with a three-unit deal across the Salt Lake City area</li> <li xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Dan Karraker</b> is further ...</li></ul><p><a href=https://www.benzinga.com/pressreleases/26/05/n52795502/sola-salons-builds-q1-momentum-with-new-signings-openings-and-enhanced-2026-fdd?utm_source=benzinga_taxonomy&amp;utm_medium=rss_feed_free&amp;utm_content=taxonomy_rss&amp;utm_campaign=channel alt=Sola Salons Builds Q1 Momentum with New Signings, Openings and Enhanced 2026 FDD>Full story available on Benzinga.com</a></p> Corporate Expansion Retail Sales Press Releases Tue, 26 May 2026 20:50:00 +0000 PRNewswire 52795502 at https://www.benzinga.com https://www.benzinga.com/pressreleases/26/05/g52794558/college-savings-plans-network-celebrates-529-day?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p>Washington, DC, May 26, 2026 (GLOBE NEWSWIRE) -- To commemorate national 529 Day (May 29th), college savings programs across the country are using unique ways to raise awareness about the importance of saving for higher education. Leading these initiatives are members of the <a href="https://www.globenewswire.com/Tracker?data=Mq5jyctbI3aGOx0PY3zGnKYqYN0kVpwVAiFJ9FrBOr1brCJWhPT3LDXlWp0FT_BAjVU_SXwUuhdpNaLlPJTG07Qt7f2JRIhh5YIvarqSedy72fOrnsQS3gA2T5xZQdzG" rel="nofollow" target="_blank" rel="nofollow">College Savings Plans Network (CSPN</a>), a network of the <a href="https://www.globenewswire.com/Tracker?data=l9PaSArU7r9CYUKGFstXu2u5qeK9GMgU3d1cFbvVff2p4eOXNXrtqRckUFklro7SP8X1IjhE9bDol2XsyvR44ML08ChqHf8ul2btXQVBMjSXk66_XBsZ0ssF-ySkx8c3" rel="nofollow" target="_blank" rel="nofollow">National Association of State Treasurers</a> (NAST), the leading objective source of information about Section 529 college savings plans and prepaid tuition plans. </p> <p>Over the last 30 years, CSPN has tracked data which shows that American families are taking advantage of these tax-advantaged savings accounts. As of December 31, 2025, national savings in 529 savings plans surpassed $602 billion in more than 17.68 million accounts. A recent compilation of national data can be found <a href="https://www.globenewswire.com/Tracker?data=n8vA11m2uU8VpLcDipoEruyeu2dsMBfv2ikUQob3JOAw5yvr8Stfirgg3GZ9Zdnq8Pt9V85pxU7OjhWzqXUy0gc_ittAGg-zIjq6XTlsXkk=" rel="nofollow" target="_blank" rel="nofollow">here</a>. The encouraging upward trend is a promising step towards combatting student debt, which currently amounts to almost $1.84 trillion in the United States.</p> <p>"It&#039;s fitting that 529 Day falls during graduation season," said <strong>CSPN Chair and Kansas State Treasurer Steven Johnson</strong>. "This time of year reminds us that the transition into adulthood often begins shortly after high school graduation. 529 Day celebrates the flexibility and tax-advantaged benefits of 529 plans, which remain one of the best tools families can use to help prepare their students for a successful future."</p> <p>Below is a sampling of the efforts happening nationally to encourage more Americans to save for education needs in a 529 plan in celebration of 529 Day: </p> <ul> <li><strong>Alabama: </strong>As part of the CollegeCounts 5/29 Day Giveaway, we&#39;re offering the chance to win a $529 contribution to a CollegeCounts account for 29 Alabama babies born between 5/29/25 and 5/29/26 <a href="http://collegecounts529.com/giveaway" rel="nofollow" target="_blank" rel="nofollow">collegecounts529.com/giveaway</a></li> <li><strong>Alaska: </strong>Alaska 529 is sponsoring the Cook Inlet Conference Regional Baseball Tournament in Anchorage and will be coordinating family-friendly special events at the games. T. Rowe Price 529 will celebrate 529 Day by partnering with SavingforCollege.com to present a webinar answering the most common questions about 529 plans and education savings. Join a panel of 529 experts on May 28th at 1:00PM for valuable perspectives to inform your education savings journey. <a href="https://us02web.zoom.us/webinar/register/1117768024277/WN_gD5oyCp1RXOYYrY_cBYq-w" rel="nofollow" target="_blank" rel="nofollow">https://us02web.zoom.us/webinar/register/1117768024277/WN_gD5oyCp1RXOYYrY_cBYq-w</a></li> <li><strong>Arizona:</strong> On May 29th, Arizona Treasurer Kimberly Yee will be surprising one lucky newborn with $529 towards a new AZ529 Education Savings Plan! In recognition of 529 Day, Treasurer Yee will stop by a Phoenix hospital to surprise the newborn along with parents and family, who just had their bundle of joy. Along with a new 529, Treasurer Yee will bring a gift basket filled with an AZ529 newborn onesie, blanket and even an astronaut costume, just to encourage the family to dream about their baby&#39;s future. This will be the 3rd year Treasurer Yee has surprised a newborn family to encourage them that it&#39;s never too early to start saving for their child&#39;s future education! <a href="http://www.az529.gov/" rel="nofollow" target="_blank" rel="nofollow">www.az529.gov</a></li> <li><strong>California: </strong>From May 20 through May 31, 2026, college savers will receive a $50 bonus when they open a ScholarShare 529 account for a new beneficiary using promo code 529Day26, make an initial deposit of at least $50 and set up recurring contributions of $50 per month for six consecutive months. More information, including complete terms and conditions, can be found at ScholarShare529.com/529Day2026 starting May 6.</li> <li><strong>Connecticut: </strong>CHET 529 Day at Yard Goats baseball game in Hartford, CT will take place on 5/29. Connecticut Treasurer Erick Russell will address the crowd pre-game as well as appear as a guest on Yard Goats Radio during the game. He will share the benefits of opening a CHET account and also talk about CHET&#039;s annual Dream Big! Competition for students, which begins in August and is an opportunity for K-12 students to win up to $20,000 toward their CHET 529 accounts. There will also be extensive video displays throughout the park promoting CHET.  AboutCHET.com </li> <li><strong>District of Columbia:</strong> The DC College Savings Plan will be running an Art Contest for DC residents ages 3-7. The contest will run from May 1st through May 27th. Winners will be selected on May 28th and notified on May 29th. Eight winners, one from each Ward, will be selected to receive a $529 account contribution. <a href="https://www.dccollegesavings.com/" rel="nofollow" target="_blank" rel="nofollow">https://www.dccollegesavings.com/art</a></li> <li><strong>Idaho:</strong> In Idaho, we are partnering with one of our local sports teams – the Boise Hawks – to have a special shout-out during the game. We run a promotion throughout their season where one child is selected each game to receive tickets and start the game with a "Let&#039;s play ball" announcement.  <a href="http://idsaves.org/" rel="nofollow" target="_blank" rel="nofollow">idsaves.org</a></li> <li><strong>Indiana: </strong>Celebrate 5.29 Day with a chance to boost your little Hoosier&#39;s future. Enter the 5.29 Day Big Futures Sweepstakes from Indiana529 for a chance to win a $529 deposit ...</li></ul><p><a href=https://www.benzinga.com/pressreleases/26/05/g52794558/college-savings-plans-network-celebrates-529-day?utm_source=benzinga_taxonomy&amp;utm_medium=rss_feed_free&amp;utm_content=taxonomy_rss&amp;utm_campaign=channel alt=College Savings Plans Network Celebrates 529 Day>Full story available on Benzinga.com</a></p> Retail Sales Press Releases Tue, 26 May 2026 20:29:18 +0000 Globe Newswire 52794558 at https://www.benzinga.com https://www.benzinga.com/pressreleases/26/05/g52793110/kailera-reports-first-quarter-2026-financial-results-and-provides-clinical-data-updates?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <ul type="disc"> <li><em>Important progress across four clinical-stage programs demonstrating depth and breadth of obesity pipeline </em></li> <li><em>Initiated five late-stage global clinical trials in obesity, including the ribupatide injection KaiNETIC Phase 3 program</em></li> <li><em>Reported positive topline clinical data from three trials conducted by our partner Hengrui in China, </em><em>including new topline data from Phase 3 trial of oral small molecule GLP-1 receptor agonist HRS-7535 (KAI-7535) in type 2 diabetes, and first-in-human topline data from Phase 1 trial for injectable tri-agonist HRS-4729 (KAI-4729)</em></li> <li><em>Cash on hand, including IPO proceeds, is expected to fund operations into mid-2028</em></li> </ul> <p>WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/KLRA" rel="nofollow">KLRA</a>) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today reported financial results for the first quarter ended March 31, 2026, and provided a summary of recent business highlights.</p> <p>"During the quarter, we continued to build meaningful momentum and made significant progress advancing our clinical portfolio, including initiating several clinical trials and reporting important data readouts that further underscore the breadth, depth, and potential of our pipeline," said Ron Renaud, President and Chief Executive Officer of Kailera. "Importantly, our ribupatide franchise continues to demonstrate category-leading potential among obesity management medications, highlighted by the initiation of the global KaiNETIC Phase 3 program for ribupatide injection and positive Phase 2 data for ribupatide oral in China. We are also pleased to announce new topline data for HRS-7535 (KAI-7535) and HRS-4729 (KAI-4729) that reflect the shared commitment with our partner to advance a diverse portfolio with multiple mechanisms and injectable and oral modalities to help address the diverse and evolving needs of people living with obesity."</p> <p>Renaud, continued, "These achievements, combined with our successful IPO, have positioned us with the capital and operational strength to continue advancing multiple programs in parallel. We are focused on maintaining this momentum and executing across our clinical programs as we work to deliver differentiated therapies for the treatment of obesity."</p> <p><strong>First Quarter Business Highlights and Recent Developments</strong></p> <p><strong><em>Pipeline Highlights</em></strong></p> <ul type="disc"> <li style="margin-top:12pt; margin-bottom:8pt;"><strong>Ribupatide injection (KAI-9531), GLP-1/GIP receptor dual agonist: </strong><br /> <ul type="circle"> <li style="margin-top:12pt; margin-bottom:8pt;"><a href="https://investors.kailera.com/news-releases/news-release-details/kailera-therapeutics-announces-first-participants-randomized" rel="nofollow" target="_blank" rel="nofollow"><strong>Initiated</strong></a><strong> global Phase 3 </strong><strong>KaiNETIC</strong><strong> program</strong><strong>: </strong>The program encompasses three double-blind, randomized, placebo-controlled Phase 3 trials (KaiNETIC-1, KaiNETIC-2, and KaiNETIC-3) evaluating once-weekly ribupatide injection doses of up to 10 mg over 76 weeks in adults living with obesity or overweight. Data is anticipated in 2028.</li> <li style="margin-top:12pt; margin-bottom:8pt;"><strong>Initiated U.S. Phase 2b high dose obesity clinical trial to evaluate the potential to achieve even greater weight loss with higher doses of ribupatide injection:</strong> The randomized, double-blind, placebo-controlled trial is expected to enroll approximately 250 participants with a BMI of 35 or greater and no type 2 diabetes (T2D). Participants will receive either placebo or doses up to 20 mg of ribupatide injection administered over a period of 48 weeks. Data is anticipated in 2027.</li> <li style="margin-top:12pt; margin-bottom:8pt;"><a href="https://investors.kailera.com/news-releases/news-release-details/hengrui-pharma-and-kailera-therapeutics-announce-clinical-data" rel="nofollow" target="_blank" rel="nofollow"><strong>Announced</strong></a> <strong>data </strong><strong>presentation at the 86th Scientific Sessions of the American Diabetes Association (ADA</strong><strong> 2026</strong><strong>)</strong><strong>:</strong> Poster presentation will cover Kailera&#039;s Phase 1 single ascending dose bridging study of ribupatide injection in participants of non-Asian and Asian descent, which supported the initiation of the ongoing global Phase 3 KaiNETIC clinical program.</li> </ul> </li> <li style="margin-top:12pt; margin-bottom:8pt;"><strong>Ribupatide oral (KAI-9531-T), GLP-1/GIP receptor dual agonist:</strong><br /> <ul type="circle"> <li style="margin-top:12pt; margin-bottom:8pt;"><a href="https://investors.kailera.com/news-releases/news-release-details/kailera-therapeutics-and-hengrui-pharma-report-positive-topline" rel="nofollow" target="_blank" rel="nofollow"><strong>Reported</strong></a><strong> positive topline data from Hengrui&#039;s Phase 2 </strong><strong>obesity </strong><strong>trial</strong><strong>:</strong> Participants taking ribupatide oral achieved a mean weight loss of up to 12.1% with no observed plateau at Week 26, and up to 38.6% of participants taking ribupatide oral achieved at least 15% weight loss. Results demonstrated a potentially highly differentiated tolerability profile with low rates of gastrointestinal adverse events observed. The full data will be presented in a poster presentation at ADA 2026.</li> <li style="margin-top:12pt; margin-bottom:8pt;">Subject to discussions with the FDA and other regulatory agencies, Kailera plans to initiate Phase 3 global trials as early as the first half of 2027.</li> </ul> </li> <li style="margin-top:12pt; margin-bottom:8pt;"><strong>KAI-7535, oral small molecule GLP-1 receptor agonist: </strong><br /> <ul type="circle"> <li style="margin-top:12pt; margin-bottom:8pt;"><strong>Initiated global Phase 2 obesity trial: </strong>The double-blind, randomized, placebo-controlled trial is expected to enroll approximately 320 participants with a BMI of 30+ or a BMI of 27+ with at least one co-morbidity, which may include T2D. Participants will receive either placebo or doses up to 360 mg of KAI-7535 administered over a period of 44 weeks. Data is anticipated in 2027.</li> <li style="margin-top:12pt; margin-bottom:8pt;"><strong>Reported positive topline data from OUTSTAND-1, Hengrui&#039;s Phase 3 T2D clinical trial </strong>(<a href="https://clinicaltrials.gov/study/NCT06672172?term=HRS-7535&amp;viewType=Card&amp;rank=2" rel="nofollow" target="_blank" rel="nofollow"><strong>NCT06672172</strong></a><strong>)</strong>: OUTSTAND-1, the first of multiple Phase 3 trials, met the primary endpoint at Week 32, demonstrating significant HbA1c reductions across all three HRS-7535 (KAI-7535) dose levels (30 mg, 60 mg, and 90 mg) compared to placebo. The multi-center, randomized, double-blind, placebo-controlled trial was designed to evaluate the efficacy and safety of HRS-7535 in adult participants with T2D. The trial enrolled 284 participants with T2D with a mean baseline HbA1c of 7.95%, mean baseline body weight of 77.5 kg (171 lbs.) and mean body mass index (BMI) of 27.8 kg/m²and a median T2D duration of 1.60 years at baseline. Prior use of glucose-lowering medication was reported by 33.5% of the participants. The participant population was 33.1% female.<br /> <ul type="square"> <li style="margin-top:12pt; margin-bottom:8pt;">Based on the efficacy estimand¹, HbA1c reductions ranged from 1.40% to 1.68%, compared to 0.06% for placebo. Based on the treatment policy estimand², HbA1c reductions ranged from 1.38% to 1.63%, compared to 0.18% for placebo. HRS-7535 also demonstrated clinically meaningful benefit across multiple metabolic and organ function measures, including reduction in weight, urinary protein and blood pressure, and improvements in blood lipids.</li> <li style="margin-top:12pt; margin-bottom:8pt;">The trial results demonstrated favorable safety and tolerability data consistent with oral GLP-1-based treatments and previously reported HRS-7535 Phase 2 clinical data. Most treatment-emergent adverse events (TEAEs) were mild to moderate and gastrointestinal-related. No Grade 3 hypoglycemic events were reported, and no liver safety signal was observed.</li> <li style="margin-top:12pt; margin-bottom:8pt;">Hengrui intends to share the full HRS-7535 Phase 3 T2D clinical trial data at an upcoming scientific conference, and plans to submit an NDA for HRS-7535 for the treatment of T2D in China.</li> <li style="margin-top:12pt; margin-bottom:8pt;">Data from Hengrui&#039;s ongoing Phase 3 clinical trial in participants living with obesity is anticipated later this year.</li> </ul> </li> </ul> </li> <li style="margin-top:12pt; margin-bottom:8pt;"><strong>KAI-4729, injectable GLP-1/GIP/glucagon receptor tri-agonist:</strong><br /> <ul type="circle"> <li style="margin-top:12pt; margin-bottom:8pt;"><strong>Reported positive topline data from Hengrui&#039;s Phase 1 SAD/MAD trial </strong>(<a href="https://clinicaltrials.gov/study/NCT06762600?term=HRS-4729&amp;viewType=Card&amp;rank=1" rel="nofollow" target="_blank" rel="nofollow"><strong>NCT06762600</strong></a><strong>):</strong> The randomized, double-blind, placebo-controlled first-in-human trial evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-4729 (KAI-4729) injection in healthy participants. The MAD portion of Phase 1 trial of KAI-4729 enrolled 60 participants with a mean baseline body weight of 87.3 kg (192 lbs) and mean baseline body mass index (BMI) of 31.4 kg/m². Participants received once-weekly doses of 1 mg, 4 mg, 8 mg or 12 mg HRS-4729, 4 mg ribupatide (active control) or placebo for 12 weeks.<br /> <ul type="square"> <li style="margin-top:12pt; margin-bottom:8pt;">HRS-4729 demonstrated linear pharmacokinetics, with a half-life of approximately 4 to 5 days, supporting once-weekly dosing.</li> <li style="margin-top:12pt; margin-bottom:8pt;">In the MAD portion of the trial at Week 12, participants receiving multiple doses of 12 mg of HRS-4729 achieved a mean weight loss of up to 16.0% from baseline, compared to 5.4% with placebo.</li> <li style="margin-top:12pt; margin-bottom:8pt;">HRS-4729 demonstrated favorable safety and tolerability data consistent with GLP-1-based treatments. Most treatment-emergent adverse events (TEAEs) were mild to moderate and gastrointestinal-related.</li> <li style="margin-top:12pt; margin-bottom:8pt;">HRS-4729 demonstrated dose-dependent reduction in liver fat content as measured by magnetic resonance imaging proton density fat fraction.</li> <li style="margin-top:12pt; margin-bottom:8pt;">Hengrui intends to share the full HRS-4729 Phase 1 clinical trial data at an upcoming scientific conference.</li> <li style="margin-top:12pt; margin-bottom:8pt;">Hengrui plans to advance HRS-4729 to Phase 2 clinical trials including for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH) in China, and Kailera plans to initiate a Phase 1 clinical trial outside of China in 2026, with data expected in 2027.</li> </ul> </li> </ul> </li> </ul> <p><strong><em>Corporate Highlights</em></strong></p> <ul type="disc"> <li style="margin-top:12pt; margin-bottom:8pt;"><strong>Expanded leadership team with key appointments:</strong><br /> <ul type="circle"> <li>Appointed Martin Mackay, Ph.D. and Shelley Liu, Ph.D to <a href="https://www.kailera.com/leadership/#board-of-directors" rel="nofollow" target="_blank" rel="nofollow">Board of Directors</a>. Dr. Mackay brings more than 30 years of biopharmaceutical leadership experience overseeing research and development (R&amp;D) across leading pharmaceutical and biotechnology companies and helping to advance transformative medicines across multiple therapeutic areas and through every stage of development. Dr. Liu, China Head of Corporate Development at Hengrui, brings expertise in evaluating R&amp;D innovation and advising on corporate development strategy across the healthcare industry.</li> </ul> </li> <li><strong>Closed $718.8M Initial Public Offering:</strong><br /> <ul type="circle"> <li><a href="https://investors.kailera.com/news-releases/news-release-details/kailera-announces-closing-initial-public-offering-and-full" rel="nofollow" target="_blank" rel="nofollow">Closed</a> initial public offering of 44,921,875 shares of its common stock at the initial public offering price of $16.00 per share. All of the shares of common stock were offered by Kailera and gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were $718.8 million. Kailera began trading on the Nasdaq Global Select Market under the ticker symbol "KLRA" on April 17, 2026.</li> </ul> </li> </ul> <p><strong>Anticipated Key Milestones</strong></p> <ul type="disc"> <li><strong>Ribupatide injection: </strong>U.S. Phase 2b high dose obesity data anticipated in 2027; global Phase 3 obesity data anticipated in 2028</li> <li><strong>Ribupatide oral:</strong> Initiate global Phase 3 obesity trials as early as 1H&#039;2027</li> <li><strong>KAI-7535: </strong>Global Phase 2 obesity data anticipated in 2027</li> <li><strong>KAI-4729:</strong> Initiate Phase 1 trial by end of year 2026; data anticipated in 2027</li> </ul> <p><strong>First Quarter 2026 Financial Results</strong></p> <p>As of March 31, 2026, Kailera had cash, cash equivalents and marketable securities of $581.9 million, which, together with the $718.8 million of gross proceeds raised as part of its initial public offering, is expected to fund operations into mid-2028.</p> <p>R&amp;D expenses were $70.9 million for the quarter ended March 31, 2026, compared to $10.1 million for the same period in 2025. The increase of $60.7 million was primarily driven by the increase in product candidate development and the related nonclinical, clinical, and contract manufacturing costs associated with the Company&#39;s portfolio, as well as the increase in personnel-related costs to support its ongoing R&amp;D activities.</p> <p>General and administrative expenses were $13.8 million for the quarter ended March 31, 2026, compared to $10.3 million for the same period in 2025. The increase of $3.5 million was primarily driven by personnel-related costs and professional service costs as the Company continues to expand its operations.</p> <p>Net loss was $78.9 million for the quarter ended March 31, 2026, compared to a net loss of $18.0 million for the same period in 2025.</p> <p><strong>Upcoming Events</strong></p> <p>Kailera expects to participate in the following investor conferences and medical congresses:</p> <ul type="disc"> <li style="margin-top:12pt; margin-bottom:12pt;">Jefferies Global Healthcare Conference – June 4, 2026</li> <li>American Diabetes Association Scientific Sessions – June 5-8, 2026</li> </ul> <p><strong>About Kailera Therapeutics</strong></p> <p>Kailera Therapeutics (Kailera) is a clinical-stage biotechnology company focused on elevating the next era of obesity care by progressing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. With an obesity-first focus, Kailera is advancing four clinical-stage product candidates leveraging multiple GLP-1-based mechanisms of action and routes of administration specifically designed to address critical needs in the current therapeutic landscape with a lead product candidate, ribupatide injection (also known as KAI-9531), that has the potential for the greatest weight loss. Ribupatide injection is in global Phase 3 trials as a once-weekly injectable GLP-1/GIP receptor dual agonist. Kailera is expanding the ribupatide franchise by developing a once-daily oral formulation with the goal of providing an oral option with the potential for compelling weight loss and highly differentiated tolerability. Additionally, Kailera is advancing the development of KAI-7535, a once-daily oral small molecule GLP-1 receptor agonist, and KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera&#039;s vision is to deliver category-leading obesity management ...</p><p><a href=https://www.benzinga.com/pressreleases/26/05/g52793110/kailera-reports-first-quarter-2026-financial-results-and-provides-clinical-data-updates?utm_source=benzinga_taxonomy&amp;utm_medium=rss_feed_free&amp;utm_content=taxonomy_rss&amp;utm_campaign=channel alt=Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates>Full story available on Benzinga.com</a></p> Earnings KLRA Retail Sales Press Releases Tue, 26 May 2026 20:02:00 +0000 Globe Newswire 52793110 at https://www.benzinga.com https://www.benzinga.com/pressreleases/26/05/b52789034/jama-neurology-publishes-phase-3-data-on-d1-receptor-antagonist-ecopipam-in-tourette-syndrome?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel <p xmlns="http://www.w3.org/1999/xhtml"> <i xmlns="http://www.w3.org/1999/xhtml">Phase 3 data show delayed time to relapse and maintained tic improvement with investigational, first-in-class mechanism targeting dopamine pathway</i></p> <p xmlns="http://www.w3.org/1999/xhtml"> Phase 3 results published in <i xmlns="http://www.w3.org/1999/xhtml">JAMA Neurology</i> showed that ecopipam, an investigational, first-in-class dopamine-1 (D1) receptor antagonist, delayed time to relapse compared to placebo and maintained clinically meaningful tic improvement in subjects with Tourette syndrome for up to 24 weeks.</p> <p xmlns="http://www.w3.org/1999/xhtml"> Emalex Biosciences is developing ecopipam, which targets the D1 receptor, a pathway implicated in tic expression. The mechanism represents a new class of investigational therapies for Tourette syndrome.</p> <p xmlns="http://www.w3.org/1999/xhtml"> In the randomized withdrawal Phase 3 trial, ecopipam significantly delayed the time to relapse compared with placebo in pediatric participants and in the overall study population and maintained clinically meaningful improvements in tic severity for up to 24 weeks of treatment. The results of the study showed that ecopipam significantly delayed the time to relapse compared to placebo in both the pediatric population (HR = 0.5, P = 0.0084) and a combined population of both pediatric and adults (HR = 0.5, P = 0.0050).</p> <p xmlns="http://www.w3.org/1999/xhtml"> "Tourette syndrome can affect nearly every part of a person&#039;s life, yet treatment options remain limited," said Frederick E. Munschauer, MD, Chief Medical Officer of Emalex Biosciences. "These Phase 3 data show that targeting the D1 receptor ...</p><p><a href=https://www.benzinga.com/pressreleases/26/05/b52789034/jama-neurology-publishes-phase-3-data-on-d1-receptor-antagonist-ecopipam-in-tourette-syndrome?utm_source=benzinga_taxonomy&amp;utm_medium=rss_feed_free&amp;utm_content=taxonomy_rss&amp;utm_campaign=channel alt=JAMA Neurology Publishes Phase 3 Data on D1 Receptor Antagonist Ecopipam in Tourette Syndrome>Full story available on Benzinga.com</a></p> Retail Sales Press Releases Tue, 26 May 2026 18:01:00 +0000 Business Wire 52789034 at https://www.benzinga.com https://www.benzinga.com/pressreleases/26/05/g52787657/retail-sales-slip-in-april-as-calendar-shifts-economic-pressures-weigh-on-consumer-demand-reports-?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p>CHICAGO, May 26, 2026 (GLOBE NEWSWIRE) -- CHICAGO, May 26, 2026 — Retail performance softened in April, as challenging year-over-year comparisons and sustained economic pressures weighed heavily on consumer demand. Overall retail spending declined 1.6% compared to April 2025, while unit demand fell 4.7%, reflecting a cautious consumer environment across multiple sectors, according to <a href="https://www.globenewswire.com/Tracker?data=1ESS7aR2kW2DxUlOiAzRCMTVCRw_eABfhT4ATBPbKaHyWNi7X197prKb-DpYtabo48l1q6i8eM499WhSoma-LQ==" rel="nofollow" target="_blank" rel="nofollow">Circana</a><u>, LLC.</u> The decline was driven in part by calendar-related distortions. The Easter holiday shifted into March this year, creating an unfavorable comparison for April results. Additionally, elevated pricing in key categories last year — particularly eggs during the height of avian flu disruptions — further complicated year-over-year performance metrics. </p> <p>During the four weeks ending May 2, 2026, Circana reports notable declines in key retail sectors. Retail food and beverage dollar sales decreased 1.7%, with a 4% drop in unit sales. Non-edible consumer packaged goods (CPG) revenue dipped 0.7%, while unit demand was down 5.8%. Discretionary general merchandise sales revenue fell 2.1%, with a 10.9% drop in units. </p> <p>"Current retail results are clouded. ...</p><p><a href=https://www.benzinga.com/pressreleases/26/05/g52787657/retail-sales-slip-in-april-as-calendar-shifts-economic-pressures-weigh-on-consumer-demand-reports-?utm_source=benzinga_taxonomy&amp;utm_medium=rss_feed_free&amp;utm_content=taxonomy_rss&amp;utm_campaign=channel alt=Retail Sales Slip in April as Calendar Shifts, Economic Pressures Weigh on Consumer Demand, Reports Circana>Full story available on Benzinga.com</a></p> Retail Sales Press Releases Tue, 26 May 2026 17:19:35 +0000 Globe Newswire 52787657 at https://www.benzinga.com https://www.benzinga.com/pressreleases/26/05/n52786689/prezent-vivo-and-nested-knowledge-partner-to-bring-ai-powered-competitive-intelligence-to-life-sci?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel <p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">The alliance fuses Prezent Vivo&#39;s AI + human expertise model with Nested Knowledge&#39;s evidence synthesis platform, so Life Sciences teams arrive at every congress and every month with the insights they need, tailored to their specific challenges.</b></p> <p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">PALO ALTO, Calif. and ST. PAUL, Minn.</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">May 26, 2026</span> /PRNewswire/ -- <b xmlns="http://www.w3.org/1999/xhtml">Prezent Vivo</b>, the leading AI-powered business communication solution for Life Sciences enterprises, and <b xmlns="http://www.w3.org/1999/xhtml">Nested Knowledge</b>, the premier AI platform for living systematic literature reviews and automated evidence synthesis, today announced a strategic partnership that redefines how pharmaceutical and biotech teams prepare for medical congresses and stay ahead of the competitive landscape year-round.</p> <div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p xmlns="http://www.w3.org/1999/xhtml"> <a xmlns="http://www.w3.org/1999/xhtml" href="https://mma.prnewswire.com/media/2987999/Prezent__Prezent_Vivo_Partners_with_Nested_Knowledge.html" target="_blank" rel="nofollow" rel="nofollow"><br /> <img xmlns="http://www.w3.org/1999/xhtml" src="https://mma.prnewswire.com/media/2987999/Prezent__Prezent_Vivo_Partners_with_Nested_Knowledge.jpg" title="Prezent Vivo Partners with Nested Knowledge" alt="Prezent Vivo Partners with Nested Knowledge" /><br /> </a> </p> </div> <p xmlns="http://www.w3.org/1999/xhtml">The collaboration combines <a xmlns="http://www.w3.org/1999/xhtml" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4696644-1&amp;h=3884677011&amp;u=https%3A%2F%2Fwww.prezent.ai%2F%3Futm_source%3Dpr%26utm_medium%3Dnewswire%26utm_campaign%3Dnestedknowledge&amp;a=Prezent+Vivo" target="_blank" rel="nofollow" rel="nofollow">Prezent Vivo</a>&#39;s AI + human expertise model which transforms raw evidence into polished, audience-ready communication deliverables at speed and <a xmlns="http://www.w3.org/1999/xhtml" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4696644-1&amp;h=2624883706&amp;u=https%3A%2F%2Fnested-knowledge.com%2F%3Futm_source%3Dpr%26utm_medium%3Dnewswire%26utm_campaign%3Dprezentvivo&amp;a=Nested+Knowledge" target="_blank" rel="nofollow" rel="nofollow">Nested Knowledge</a>&#39;s AutoLit<sup xmlns="http://www.w3.org/1999/xhtml">&#xAE;</sup> synthesis engine, capable of completing rapid reviews in under 30 minutes and cutting systematic review time by more than 70%.</p> <p xmlns="http://www.w3.org/1999/xhtml">The result: teams that once spent weeks preparing for a single congress can now receive curated, congress-ready competitive intelligence packages before the first abstract session begins, alongside monthly living-evidence updates throughout the year.</p> <p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">A Strategic Partnership for Insight-Driven Life Science Communications</b></p> <p xmlns="http://www.w3.org/1999/xhtml">As trusted communications partners to leading life sciences organizations, Prezent Vivo and Nested Knowledge identified a persistent operational gap: critical evidence and competitive insights were readily available, but often not translated into formats that medical, commercial, and launch teams could quickly operationalize for decision-making and execution.</p> <p xmlns="http://www.w3.org/1999/xhtml">Teams preparing for congresses, launch planning, and competitor readouts often spent valuable time translating fragmented evidence into usable communications. Recognizing growing demand for faster, insight-driven decision support, the companies partnered to create an integrated solution that combines evidence synthesis with AI-powered scientific communications.</p> <p xmlns="http://www.w3.org/1999/xhtml"><i xmlns="http://www.w3.org/1999/xhtml">&#34;Keith and I were talking about how much intelligence exists in life sciences, and how hard it is for field-facing teams to actually use it when it matters. We both saw immediately that we could do something really special here—reaching more teams, ...</i></p><p><a href=https://www.benzinga.com/pressreleases/26/05/n52786689/prezent-vivo-and-nested-knowledge-partner-to-bring-ai-powered-competitive-intelligence-to-life-sci?utm_source=benzinga_taxonomy&amp;utm_medium=rss_feed_free&amp;utm_content=taxonomy_rss&amp;utm_campaign=channel alt=Prezent Vivo and Nested Knowledge Partner to Bring AI-Powered Competitive Intelligence to Life Sciences Teams>Full story available on Benzinga.com</a></p> Licensing/Marketing Agreements New Products/Services Publishing/Information Services Retail Sales Press Releases Tue, 26 May 2026 16:51:00 +0000 PRNewswire 52786689 at https://www.benzinga.com https://www.benzinga.com/pressreleases/26/05/n52784679/new-med-to-manage-tourette-syndrome-shows-promise-in-phase-iii-clinical-trial?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel <p xmlns="http://www.w3.org/1999/xhtml" class="prntac"><i xmlns="http://www.w3.org/1999/xhtml">Emalex Biosciences to use data from research led by Cincinnati Children&#39;s to seek FDA approval for ecopipam, the first drug designed to treat children with motor and vocal tics</i></p> <p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">CINCINNATI</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">May 26, 2026</span> /PRNewswire/ -- Continued use of a drug called ecopipam can cut the risk of relapse in half for children battling tics caused by Tourette syndrome (TS).</p> <div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p xmlns="http://www.w3.org/1999/xhtml"> <a xmlns="http://www.w3.org/1999/xhtml" href="https://mma.prnewswire.com/media/404302/Cincinnati_Childrens_Hospital_Logo.html" target="_blank" rel="nofollow" rel="nofollow"><br /> <img xmlns="http://www.w3.org/1999/xhtml" src="https://mma.prnewswire.com/media/404302/Cincinnati_Childrens_Hospital_Logo.jpg" title="" alt="" /><br /> </a> </p> </div> <p xmlns="http://www.w3.org/1999/xhtml">That&#39;s the key finding published <a xmlns="http://www.w3.org/1999/xhtml" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4696559-1&amp;h=1864958617&amp;u=https%3A%2F%2Fjamanetwork.com%2Fjournals%2Fjamaneurology%2Ffullarticle%2F2849573&amp;a=May+26%2C+2026%2C+in+JAMA+Neurology" target="_blank" rel="nofollow" rel="nofollow">May 26, 2026, in <i xmlns="http://www.w3.org/1999/xhtml">JAMA Neurology</i></a> describing the results of a recently completed phase III clinical trial of the first drug designed to help children with this condition. Next step: the drug maker Emalex Biosciences plans to seek approval from the U.S. Food and Drug Administration to take the new medicine to market.</p> <p xmlns="http://www.w3.org/1999/xhtml">The principal investigator for the 77-site clinical trial was <a xmlns="http://www.w3.org/1999/xhtml" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4696559-1&amp;h=4258026964&amp;u=https%3A%2F%2Fwww.cincinnatichildrens.org%2Fbio%2Fg%2Fdonald-gilbert&amp;a=Donald+Gilbert%2C+MD%2C+MS" target="_blank" rel="nofollow" rel="nofollow">Donald Gilbert, MD, MS</a>, a movement disorders expert with the Division ...</p><p><a href=https://www.benzinga.com/pressreleases/26/05/n52784679/new-med-to-manage-tourette-syndrome-shows-promise-in-phase-iii-clinical-trial?utm_source=benzinga_taxonomy&amp;utm_medium=rss_feed_free&amp;utm_content=taxonomy_rss&amp;utm_campaign=channel alt=New Med to Manage Tourette Syndrome Shows Promise in Phase III Clinical Trial>Full story available on Benzinga.com</a></p> Polls & Research Surveys Retail Sales Press Releases Tue, 26 May 2026 15:58:00 +0000 PRNewswire 52784679 at https://www.benzinga.com https://www.benzinga.com/pressreleases/26/05/g52784325/loblaw-april-food-inflation-report?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p>TORONTO, May 26, 2026 (GLOBE NEWSWIRE) -- In the latest edition of its <a href="https://www.globenewswire.com/Tracker?data=8JvYvgU4FLTrYKoOfd6lHh46nRhR0QGLqSZecFm0zJLPsMTzlK1ShlWrJlrt8eVWVRflRiv3GN1e1mFJlSx8SxzHx35W1TLRLW-DIWINvntoGmc-1Ksj44Klj4-mdU01Z2acABpx2tUUl6MmVTVTCAmkmoz9nz9hhp7Py0F2xafrJieOdisKA3oZv2zGNk1ln7rVlW11RQbckokmaVbolvA5sYP1pyGqmOUIL-MpvPkHSLlmScggJ3oGiAaVjeeuKGxbDJ6GaEsvVMZJsuIycXlBk-uSPKM_noiHO_JsLWQ=" rel="nofollow" target="_blank" rel="nofollow">Food Inflation Report</a>, Loblaw is pleased to provide context around what&#039;s impacting food prices – now and into the future. This report follows ...</p><p><a href=https://www.benzinga.com/pressreleases/26/05/g52784325/loblaw-april-food-inflation-report?utm_source=benzinga_taxonomy&amp;utm_medium=rss_feed_free&amp;utm_content=taxonomy_rss&amp;utm_campaign=channel alt=Loblaw April Food Inflation Report>Full story available on Benzinga.com</a></p> Advisory TSX:L Retail Sales Restaurants Press Releases General Tue, 26 May 2026 15:48:12 +0000 Globe Newswire 52784325 at https://www.benzinga.com https://www.benzinga.com/pressreleases/26/05/n52781080/new-analysis-shows-tryngolza-olezarsen-reduced-acute-pancreatitis-by-85-and-triglycerides-by-66-in?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel <p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">STOCKHOLM</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">May 26, 2026</span> /PRNewswire/ -- Sobi&#xAE; (STO: SOBI) today announced results from a new analysis of the pivotal Phase 3 CORE and CORE2 trials, showing Tryngolza&#xAE; (olezarsen) reduced the relative risk of acute pancreatitis events by 85% (P&lt;0.001) and reduced triglycerides by 66% in patients with severe hypertriglyceridemia (sHTG) after six months.<sup xmlns="http://www.w3.org/1999/xhtml">[1]</sup></p> <p xmlns="http://www.w3.org/1999/xhtml">The pooled subgroup analysis, presented as a late breaking abstract at the European Atherosclerosis Society (EAS) 2026 Congress in Athens, Greece, included 455 patients with baseline triglycerides of ≥880 mg/dL (~10 mmol/L), defined by the EAS as severe hypertriglyceridemia. At six months, patients randomised to receive olezarsen 80 mg showed a placebo-adjusted reduction in triglycerides of 66%, and those on olezarsen 50 mg a 59% reduction (each P&lt;0.001). Overall, 85% of olezarsen-treated patients achieved triglycerides of &lt;10 mmol/L.<sup xmlns="http://www.w3.org/1999/xhtml">1</sup></p> <p xmlns="http://www.w3.org/1999/xhtml">&#34;Acute pancreatitis is a painful and potentially life-threatening condition that often requires urgent hospitalisation. People with triglyceride levels above 10 mmol/L have a four times greater risk of acute pancreatitis compared to those with ideal low levels, and this risk increases progressively as triglyceride levels rise<sup xmlns="http://www.w3.org/1999/xhtml">[2]</sup>. According to EAS/ESC guidelines, triglyceride levels above 10 mmol/L warrant urgent intervention to prevent acute pancreatitis<sup xmlns="http://www.w3.org/1999/xhtml">[3]</sup>,&#34; said Børge Nordestgaard, Professor and Chief Physician at Copenhagen University Hospital. &#34;This new analysis showed that olezarsen reduced acute pancreatitis risk by 85% in patients with baseline triglyceride levels ≥10 mmol/L, while the vast majority of patients achieved triglyceride levels below 10 mmol/L.&#34;</p> <p xmlns="http://www.w3.org/1999/xhtml">Severe hypertriglyceridemia is the third most common cause of acute pancreatitis.<sup xmlns="http://www.w3.org/1999/xhtml">[4]</sup> The incidence of acute pancreatitis globally has increased at an average annual rate of 3% since the 1960s, contributing to a growing burden on healthcare systems.<sup xmlns="http://www.w3.org/1999/xhtml">[5]</sup></p> <p xmlns="http://www.w3.org/1999/xhtml">&#34;These results add to the collective body of evidence for olezarsen, showing the reduction of acute pancreatitis risk in severe hypertriglyceridemia. As rates of acute pancreatitis continue to increase, olezarsen has the potential to be an important part of a preventative approach to disease management in at-risk patients,&#34; said Lydia Abad-Franch, MD, Research, Development and Medical Affairs, and Chief Medical Officer at Sobi.</p> <p xmlns="http://www.w3.org/1999/xhtml">The results, presented by Dr Andre Zimerman on ...</p><p><a href=https://www.benzinga.com/pressreleases/26/05/n52781080/new-analysis-shows-tryngolza-olezarsen-reduced-acute-pancreatitis-by-85-and-triglycerides-by-66-in?utm_source=benzinga_taxonomy&amp;utm_medium=rss_feed_free&amp;utm_content=taxonomy_rss&amp;utm_campaign=channel alt=New analysis shows Tryngolza® (olezarsen) reduced acute pancreatitis by 85% and triglycerides by 66% in severe hypertriglyceridemia>Full story available on Benzinga.com</a></p> SOBIS Retail Sales Press Releases Tue, 26 May 2026 14:46:00 +0000 PRNewswire 52781080 at https://www.benzinga.com https://www.benzinga.com/pressreleases/26/05/b52778599/yell-increases-monthly-new-user-acquisition-by-189-in-april-2026-accelerating-growth-across-fintec?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel <p xmlns="http://www.w3.org/1999/xhtml"> <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fyellpayment.com&amp;esheet=54540520&amp;newsitemid=20260526148274&amp;lan=en-US&amp;anchor=YELL&amp;index=1&amp;md5=0f16ffe1db04ac65f72c13becadc02fb" shape="rect" rel="nofollow">YELL</a> Services, the new consumer and merchant platform, gained early traction following its soft launch in 2025. Founder <b xmlns="http://www.w3.org/1999/xhtml">Andreas Marrendt</b>, the real estate and tech entrepreneur, brings proven cross-sector execution and strategic discipline to YELL&#039;s next phase of expansion.</p> <p xmlns="http://www.w3.org/1999/xhtml"> YELL, the fast-growing fintech platform focused on helping consumers and businesses manage money and payments, has seen new user acquisition nearly triple in April 2026, with new customer onboarding increasing 189% from the prior month of March.</p> <p xmlns="http://www.w3.org/1999/xhtml"> YELL continues to build momentum in a market ready for more modern payment solutions. This early traction reflects the company&#039;s focus on developing and scaling a product that addresses a modern money challenge: for consumers, money is increasingly spread across multiple apps and accounts, while everyday life still requires it to be moved, split, and managed. For small businesses, timely access to payments and available funds remains important to keeping pace with operational demands, growth, and cash flow needs.</p> <p xmlns="http://www.w3.org/1999/xhtml"> YELL&#039;s founder Andreas is an experienced real estate and tech entrepreneur with a strong track record of creating value across multiple sectors. He has built and led several ventures and hands-on platforms spanning real estate, fintech and finance, with a focus ...</p><p><a href=https://www.benzinga.com/pressreleases/26/05/b52778599/yell-increases-monthly-new-user-acquisition-by-189-in-april-2026-accelerating-growth-across-fintec?utm_source=benzinga_taxonomy&amp;utm_medium=rss_feed_free&amp;utm_content=taxonomy_rss&amp;utm_campaign=channel alt=YELL Increases Monthly New User Acquisition by 189% in April 2026, Accelerating Growth Across Fintech Consumer and Business Payments>Full story available on Benzinga.com</a></p> Retail Sales Press Releases Tue, 26 May 2026 14:07:00 +0000 Business Wire 52778599 at https://www.benzinga.com https://www.benzinga.com/pressreleases/26/05/g52778062/solveforce-expands-white-glove-vip-telecom-service-nationwide-eliminating-ordering-friction-for-ho?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p>Yorba Linda, CA, May 26, 2026 (GLOBE NEWSWIRE) -- <a href="https://solveforce.com/" rel="nofollow" target="_blank" rel="nofollow">SolveForce</a> today announced the nationwide expansion of its White Glove VIP Service to both residential and business customers. The premium program removes the most common frustrations in ordering telecom services — confusing plan comparisons, chasing sales representatives, and long phone queues — by providing expert, personalized human support at no additional cost.</p> <p align="center"><img alt="SolveForce Expands White Glove VIP Telecom Service Nationwide, Eliminating Ordering Friction for Homes and Businesses" height="492" src="https://pressranger.s3.us-west-1.amazonaws.com/3307046/5-Star-Suit-1200-x-628%2C-616kb.jpg" style="display:block; margin-left:auto; margin-right:auto;" width="799" /></p> <p align="center">Photo credit: VRVIRUS/Shutterstock.com</p> <p>With demand for reliable high-speed connectivity surging due to streaming, remote work, AI applications, and cloud computing, consumers and businesses are looking for better solutions. SolveForce, a leading independent telecom brokerage with more than 20 years of experience, acts as a trusted advocate that simplifies the entire process for internet, phone, and network services across 180+ providers.</p> <p><strong>For Residential Customers (Homes &amp; Families)</strong> SolveForce makes upgrading home connectivity simple and stress-free. Families needing fast, reliable internet for streaming, ...</p><p><a href=https://www.benzinga.com/pressreleases/26/05/g52778062/solveforce-expands-white-glove-vip-telecom-service-nationwide-eliminating-ordering-friction-for-ho?utm_source=benzinga_taxonomy&amp;utm_medium=rss_feed_free&amp;utm_content=taxonomy_rss&amp;utm_campaign=channel alt=SolveForce Expands White Glove VIP Telecom Service Nationwide, Eliminating Ordering Friction for Homes and Businesses>Full story available on Benzinga.com</a></p> Retail Sales Press Releases General Tue, 26 May 2026 14:00:00 +0000 Globe Newswire 52778062 at https://www.benzinga.com https://www.benzinga.com/pressreleases/26/05/g52775277/pivotal-as-a-team-member-of-the-multistate-collaborative-eipp-msce-led-by-penndot-selected-by-the-?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p align="left">PALO ALTO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Pivotal is honored to announce their participation as a team member of the Multistate Collaborative eIPP (MSCE) led by PennDOT selected by the Federal Aviation Administration (FAA) for the eVTOL Integration Pilot Program (eIPP). Pivotal^&#xAE; will be supporting the MSCE as an Original Equipment Manufacturer (OEM) of light electric vertical takeoff and landing (eVTOL) aircraft.</p> <p>With PennDOT as lead offeror, a group of peer state aviation bureaus within the NASAO AAM Multistate Collaborative (AAMMC) create the MSCE National Integration Complex with an express focus on moving the AAM industry closer to revenue and returning service to underserved cities and rural communities who otherwise don&#039;t have the funding for development - creating the best chance to bring the benefits of this new technology to the heartland of America.</p> <p>The MSCE National Integration Complex currently includes Pennsylvania, Virginia, Oklahoma, Maryland, Oregon, Massachusetts, California, North Carolina, Alaska, Illinois, Washington, Maine, New Mexico, New Jersey, Delaware, West Virginia, Wyoming, and Tennessee, three OEMs (BETA, Electra, and Pivotal), and four Operators (UPMC STAT Medevac, Nulton Aviation Tri State Charter, United Therapeutics, Republic Airways) The MSCE National Integration Complex also includes six Universities (including three FAA UAS ...</p><p><a href=https://www.benzinga.com/pressreleases/26/05/g52775277/pivotal-as-a-team-member-of-the-multistate-collaborative-eipp-msce-led-by-penndot-selected-by-the-?utm_source=benzinga_taxonomy&amp;utm_medium=rss_feed_free&amp;utm_content=taxonomy_rss&amp;utm_campaign=channel alt=Pivotal as a team member of the Multistate Collaborative eIPP (MSCE) led by PennDOT selected by the Federal Aviation Administration for the eVTOL Integration Pilot Program>Full story available on Benzinga.com</a></p> Retail Sales Press Releases General Tue, 26 May 2026 13:03:00 +0000 Globe Newswire 52775277 at https://www.benzinga.com https://www.benzinga.com/pressreleases/26/05/b52773895/redfin-reports-the-income-needed-to-afford-a-home-declined-for-seventh-straight-month-in-april?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel <ul xmlns="http://www.w3.org/1999/xhtml" class="bwlistdisc"> <li xmlns="http://www.w3.org/1999/xhtml"> <i xmlns="http://www.w3.org/1999/xhtml">Homebuying affordability improved slightly in April because mortgage rates declined while incomes rose. Still, the income required to afford a home was $29,000 higher than the typical U.S. income</i>—<i xmlns="http://www.w3.org/1999/xhtml">and mortgage rates rose again in May, potentially erasing some of the affordability gains made in April.</i> </li> <li xmlns="http://www.w3.org/1999/xhtml"> <i xmlns="http://www.w3.org/1999/xhtml">A household earning the average U.S. income would need to spend 40% of their income on the median-priced home, down from 42% a year ago</i> </li> <li xmlns="http://www.w3.org/1999/xhtml"> <i xmlns="http://www.w3.org/1999/xhtml">33% of home listings are affordable, up from 29% a year ago</i>—<i xmlns="http://www.w3.org/1999/xhtml">but down from more than 50% five years ago</i> </li> </ul> <p xmlns="http://www.w3.org/1999/xhtml"> Americans needed to earn $116,780 to afford the typical U.S. home for sale in April, down 2% from $119,191 a year earlier. That&#039;s according to a new <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.redfin.com%2Fnews%2Fincome-needed-to-buy-home-declines&amp;esheet=54541094&amp;newsitemid=20260526880888&amp;lan=en-US&amp;anchor=report&amp;index=1&amp;md5=2ce61d52feed4ec6d9a85f205957beec" shape="rect" rel="nofollow">report</a> from <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.redfin.com%2F&amp;esheet=54541094&amp;newsitemid=20260526880888&amp;lan=en-US&amp;anchor=Redfin&amp;index=2&amp;md5=2687790b6b28ac9a0541a938503dcd86" shape="rect" rel="nofollow">Redfin</a>, the real estate brokerage powered by Rocket.</p> <p xmlns="http://www.w3.org/1999/xhtml"> April marks the seventh straight month in which buying a home became more affordable on a year-over-year basis.</p> <p xmlns="http://www.w3.org/1999/xhtml"> Redfin considers a home affordable if a buyer taking out a mortgage would spend no more than 30% of their income on their monthly housing payment. This report focuses on April 2026—the most recent period for which data is available.</p> <p xmlns="http://www.w3.org/1999/xhtml"> <b xmlns="http://www.w3.org/1999/xhtml">Homebuying affordability improved because monthly housing costs are decreasing while incomes are increasing:</b></p> <ul xmlns="http://www.w3.org/1999/xhtml" class="bwlistdisc"> <li xmlns="http://www.w3.org/1999/xhtml"> Housing costs came down in April because the average 30-year fixed rate was lower than a year earlier; April&#039;s monthly average was 6.33%, down from 6.73%. </li> <li xmlns="http://www.w3.org/1999/xhtml"> The estimated median household income was $87,599, up 4% year over year. </li> </ul> <p xmlns="http://www.w3.org/1999/xhtml"> Still, the median home-sale price <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.redfin.com%2Fnews%2Fhome-prices-rise-april-2026%2F&amp;esheet=54541094&amp;newsitemid=20260526880888&amp;lan=en-US&amp;anchor=rose+2.4%25&amp;index=3&amp;md5=2f2be95caf0dde3beecfecec3c59b6e5" shape="rect" rel="nofollow">rose 2.4%</a> year over year in April, which is why affordability is improving only slightly. Note that mortgage rates jumped in May, with the weekly average hitting 6.51%. Because of that increase, house hunters locking in a rate now may not find the market more affordable than a year ago.</p> <p xmlns="http://www.w3.org/1999/xhtml"> The income required to afford a home soared in 2022 and 2023: Home prices skyrocketed amid the ...</p><p><a href=https://www.benzinga.com/pressreleases/26/05/b52773895/redfin-reports-the-income-needed-to-afford-a-home-declined-for-seventh-straight-month-in-april?utm_source=benzinga_taxonomy&amp;utm_medium=rss_feed_free&amp;utm_content=taxonomy_rss&amp;utm_campaign=channel alt=Redfin Reports the Income Needed to Afford a Home Declined For Seventh Straight Month in April>Full story available on Benzinga.com</a></p> RKT Retail Sales Press Releases Tue, 26 May 2026 12:30:00 +0000 Business Wire 52773895 at https://www.benzinga.com https://www.benzinga.com/pressreleases/26/05/n52773261/crystalys-therapeutics-doses-first-patients-in-new-phase-2-trial-of-dotinurad-for-difficult-to-tre?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel <p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">SAN DIEGO</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">May 26, 2026</span> /PRNewswire/ -- Crystalys Therapeutics Inc. (&#39;Crystalys&#39; or &#39;the Company&#39;), a clinical-stage biopharmaceutical company addressing the significant unmet medical needs of people living with gout, today announced that the first patients have been dosed in its new randomized, double-blind, placebo-controlled, multicenter Phase 2 AMETHYST study (<a xmlns="http://www.w3.org/1999/xhtml" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4693232-1&amp;h=2165769264&amp;u=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07535034%3Fterm%3DNCT07535034%26viewType%3DCard%26rank%3D1&amp;a=NCT07535034" target="_blank" rel="nofollow" rel="nofollow">NCT07535034</a>) evaluating the efficacy of dotinurad in participants with gout who are intolerant to xanthine oxidase inhibitors (XOIs) or have failed uricase treatment.</p> <div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p xmlns="http://www.w3.org/1999/xhtml"> <a xmlns="http://www.w3.org/1999/xhtml" href="https://mma.prnewswire.com/media/2784523/Crystalys_Therapeutics_Logo.html" target="_blank" rel="nofollow" rel="nofollow"><br /> <img xmlns="http://www.w3.org/1999/xhtml" src="https://mma.prnewswire.com/media/2784523/Crystalys_Therapeutics_Logo.jpg" title="Crystalys Therapeutics (PRNewsfoto/Crystalys Therapeutics)" alt="Crystalys Therapeutics (PRNewsfoto/Crystalys Therapeutics)" /><br /> </a> </p> </div> <p xmlns="http://www.w3.org/1999/xhtml">Dotinurad is a next-generation, once daily, oral URAT1 inhibitor with the potential to deliver best-in-class safety and efficacy for the treatment of gout, particularly in patients with limited treatment options.</p> <p xmlns="http://www.w3.org/1999/xhtml">&#34;Dosing the first ...</p><p><a href=https://www.benzinga.com/pressreleases/26/05/n52773261/crystalys-therapeutics-doses-first-patients-in-new-phase-2-trial-of-dotinurad-for-difficult-to-tre?utm_source=benzinga_taxonomy&amp;utm_medium=rss_feed_free&amp;utm_content=taxonomy_rss&amp;utm_campaign=channel alt=Crystalys Therapeutics Doses First Patients in New Phase 2 Trial of Dotinurad for Difficult-to-Treat Gout>Full story available on Benzinga.com</a></p> Retail Sales Press Releases Tue, 26 May 2026 12:00:00 +0000 PRNewswire 52773261 at https://www.benzinga.com